Novartis and Mochida end Japanese Diovan pact
This article was originally published in Scrip
Novartisand Mochida have let lapse a Japanese agreement for the local co-promotion of Novartis's antihypertensive Diovan (valsartan). The firms said that the early 2007 partnership had achieved its aims and that the Swiss group would market and promote the angiotensin II antagonist alone from the beginning of this year. IMS data showed that Diovan was the second biggest-selling prescription drug in Japan in the quarter to September 30th, with reimbursement-level sales rising by 5% to ¥32.4 billion ($346.2 million).
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.